The Effects of GLP-1 Analogues in Obese, Insulin-using Type 2 Diabetes in Relation to Eating Behaviour

Overview

Journal Int J Clin Pharm

Publisher Springer

Specialties Pharmacology
Pharmacy

Date 2015 Nov 25

PMID 26597956

Citations 16

Authors

Stefanie Amarens de Boer

Joop Daniel Lefrandt

Japke Frida Petersen

Hendrikus Hessel Boersma

Douwe Johannes Mulder

Klaas Hoogenberg

Affiliations

Soon will be listed here.

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies.

Objective: To evaluate GLP-1 RA treatment on body weight, glycaemic control and total daily insulin dose in obese, insulin-using type 2 diabetes patients after 2 years follow-up in a real life setting and to explore a possible relation with eating behaviour.

Setting: The Martini Hospital and the University Medical Center in Groningen in the Netherlands.

Methods: Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment. At baseline eating behaviour was classified according to the validated Dutch Eating Behaviour Questionnaire. A 2 years follow-up was performed. Main outcome measures Body weight, HbA1c and total daily insulin dose.

Results: 151 Patients started with exenatide or liraglutide. 120 patients completed the 2 years follow-up. From baseline to 2 years, body weight (mean ± SD) changed from 117.9 ± 22.1 to 107.9 ± 22.9 kg (P < 0.0001), HbA1c (median, IQR) changed from 7.9 (7.2-8.9) to 7.6 (6.9-8.3) % [63 (55-74) to 60 (52-67) mmol/mol] (P < 0.0001), total daily insulin dose changed from 90 (56-150) to 60 (0-100) Units/day (P < 0.0001). Weight change differed between eating behaviour groups (P < 0.001) in which external eating behaviour (n = 17) resulted in the smallest decline (-3.1 %) and restrained (n = 41) in the greatest (-10.3 %) in comparison with emotional (n = 37, -8.5 %) and indifferent (n = 25, -9.6 %) eating behaviours.

Conclusion: Two year of GLP-1 RA treatment resulted in a sustained reduction of weight, HbA1c and total daily insulin dose in obese, insulin-using type 2 diabetes patients in a real life setting. Largest weight loss was achieved in patients with a predominant restraint eating pattern while a predominant external eating pattern resulted in the smallest weight reduction.

Citing Articles

Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.

Pantanetti P, Cangelosi G, Alberti S, Di Marco S, Michetti G, Cerasoli G Front Endocrinol (Lausanne). 2024; 15:1394506.

PMID: 39015186 PMC: 11250060. DOI: 10.3389/fendo.2024.1394506.

Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study.

Onishi Y, Shirabe S, Eguchi K, Nishijima K, Sato T, Seino H Diabetol Int. 2023; 14(4):363-371.

PMID: 37781463 PMC: 10533472. DOI: 10.1007/s13340-023-00638-w.

A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes.

Selvarajan R, Subramanian R Diabetes Metab Syndr Obes. 2023; 16:1709-1720.

PMID: 37312901 PMC: 10259523. DOI: 10.2147/DMSO.S385196.

The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM.

Wang Q, Guo H, Mao W, Qian X, Liu Y Pharmaceutics. 2023; 15(4).

PMID: 37111687 PMC: 10143976. DOI: 10.3390/pharmaceutics15041202.

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives.

Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R Int J Mol Sci. 2023; 24(2).

PMID: 36675217 PMC: 9865319. DOI: 10.3390/ijms24021703.

References

Yamamoto H, Lee C, Marcus J, Williams T, Overton J, Lopez M . Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002; 110(1):43-52. PMC: 151031. DOI: 10.1172/JCI15595. View

Zander M, Madsbad S, Madsen J, Holst J . Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002; 359(9309):824-30. DOI: 10.1016/S0140-6736(02)07952-7. View

Toft-Nielsen M, Madsbad S, Holst J . Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999; 22(7):1137-43. DOI: 10.2337/diacare.22.7.1137. View

Drucker D, Nauck M . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548):1696-705. DOI: 10.1016/S0140-6736(06)69705-5. View

Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P . Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007; 13(5):444-50. DOI: 10.4158/EP.13.5.444. View

Herman C, Polivy J . External cues in the control of food intake in humans: the sensory-normative distinction. Physiol Behav. 2008; 94(5):722-8. DOI: 10.1016/j.physbeh.2008.04.014. View

Buse J, Rosenstock J, Sesti G, Schmidt W, Montanya E, Brett J . Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374(9683):39-47. DOI: 10.1016/S0140-6736(09)60659-0. View

Chaput J, Leblanc C, Perusse L, Despres J, Bouchard C, Tremblay A . Risk factors for adult overweight and obesity in the Quebec Family Study: have we been barking up the wrong tree?. Obesity (Silver Spring). 2009; 17(10):1964-70. DOI: 10.1038/oby.2009.116. View

Nayak U, Govindan J, Baskar V, Kalupahana D, Singh B . Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM. 2010; 103(9):687-94. DOI: 10.1093/qjmed/hcq112. View

10.

van Strien T, van der Zwaluw C, Engels R . Emotional eating in adolescents: a gene (SLC6A4/5-HTT) - depressive feelings interaction analysis. J Psychiatr Res. 2010; 44(15):1035-42. DOI: 10.1016/j.jpsychires.2010.03.012. View

11.

Vilsboll T, Christensen M, Junker A, Knop F, Gluud L . Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012; 344:d7771. PMC: 3256253. DOI: 10.1136/bmj.d7771. View

12.

Rosenstock J, Shenouda S, Bergenstal R, Buse J, Glass L, Heilmann C . Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care. 2012; 35(5):955-8. PMC: 3329851. DOI: 10.2337/dc11-1434. View

13.

Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A . Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012; 11:107. PMC: 3459720. DOI: 10.1186/1475-2840-11-107. View

14.

Schlogl H, Kabisch S, Horstmann A, Lohmann G, Muller K, Lepsien J . Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care. 2013; 36(7):1933-40. PMC: 3687323. DOI: 10.2337/dc12-1925. View

15.

Goldenberg R . Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin. 2013; 30(3):431-45. DOI: 10.1185/03007995.2013.852078. View

16.

Banos R, Cebolla A, Moragrega I, van Strien T, Fernandez-Aranda F, Aguera Z . Relationship between eating styles and temperament in an Anorexia Nervosa, Healthy Control, and Morbid Obesity female sample. Appetite. 2014; 76:76-83. DOI: 10.1016/j.appet.2014.01.012. View

17.

van Bloemendaal L, IJzerman R, Ten Kulve J, Barkhof F, Konrad R, Drent M . GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014; 63(12):4186-96. DOI: 10.2337/db14-0849. View

18.

Eng C, Kramer C, Zinman B, Retnakaran R . Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014; 384(9961):2228-34. DOI: 10.1016/S0140-6736(14)61335-0. View

19.

Dossat A, Bodell L, Williams D, Eckel L, Keel P . Preliminary examination of glucagon-like peptide-1 levels in women with purging disorder and bulimia nervosa. Int J Eat Disord. 2014; 48(2):199-205. PMC: 4155021. DOI: 10.1002/eat.22264. View

20.

van Velsen E, Lamers J, Blok V, van Leendert R, Kiewiet-Kemper R . A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice. Neth J Med. 2015; 72(10):523-7. View